ArticleMolecular and clinical oncology2016
Clinical presentation and management of uveal melanoma.
Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG).Cancers · 2026Article
- Precision prognostic model for uveal melanoma: nomogram prediction and comparison with AJCC system.Discover oncology · 2025Article
- Article
- Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.Current drug targets · 2024Review
- Article
- Article
- Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital.Journal of pathology and translational medicine · 2022Article
- A Case of Non-Irradiated Balloon Cell Melanoma of the Choroid: Expanding the Morphological Spectrum of Primary Uveal Melanomas.Diagnostics (Basel, Switzerland) · 2022Article
- Necrotic Uveal Melanoma Mimics Orbital Cellulitis: A Review.Ocular oncology and pathology · 2022Review
- Article
- Molecular characteristics of uveal melanoma and intraocular tumors.Oncology letters · 2021Review
- Identification and validation of tumor microenvironment-related lncRNA prognostic signature for uveal melanoma.International journal of ophthalmology · 2021Article
- The Tumorigenic Properties of EZH2 are Mediated by MiR-26a in Uveal Melanoma.Frontiers in molecular biosciences · 2021Article
- Role of Natural Killer Cells in Uveal Melanoma.Cancers · 2020Review
- Update on uveal melanoma: Translational research from biology to clinical practice (Review).International journal of oncology · 2020Review
- Review
- Characterization of the Pathophysiological Role of CD47 in Uveal Melanoma.Molecules (Basel, Switzerland) · 2019Article
- Differential modulation and prognostic values of immune-escape genes in uveal melanoma.PloS one · 2019Article
- Advanced choroidal melanoma with a desirable aesthetic outcome after enucleation: A case report.Oncology letters · 2018Article
- Iris extramedullary hematopoiesis in choroidal melanoma.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. The majority of the patients are Caucasian (97.8%) and aged 50-80 years. Choroidal melanoma is the predominant type (86.3%). The clinical presentation may range from no symptoms over various types of visual disturbances to visual loss. Examination includes slit-lamp biomicroscopy, indirect ophthalmoscopy and diagnostic testing, such as B-scan ultrasonography. A number of patients with posterior UM are treated with plaque radiation therapy or enucleation. At present, targeted therapy includes inhibitors of the mitogen-activated protein kinase/mitogen-activated protein kinase kinase signaling pathway. UM disseminates hematogenously, with a high propensity for metastasis to the liver, which the most common site (93% of the cases). While UM is uncommon, a significant proportion of affected patients succumb to this disease and new treatment options to improve patient survival are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.